Curateq Biologics Private Limited
- Address
- Galaxy Floors 22-24 Plot No 1, Survey No 83/1, Hyderabad Knowledge City
Sponsor Overview
Specializations
Allergic and Immunologic Disorders
Curateq Biologics Private Limited funds clinical research in chronic spontaneous urticaria, with attention to patients who have an inadequate response to H1 antihistamines and require alternative biologic treatment options.
- Chronic spontaneous urticaria
- Anti-IgE therapy
- Biosimilar monoclonal antibodies
The sponsor’s work in this area reflects interest in immune-mediated skin disease and comparative biologic treatment options.
Bone Health and Metabolic Bone Disease
The sponsor supports research in post-menopausal osteoporosis, focusing on treatment options for preserving bone mineral density and controlling markers of bone turnover.
- Post-menopausal osteoporosis
- Bone mineral density
- Bone resorption markers
This area includes interest in RANKL-targeted therapy and comparative evaluation of biologic options for skeletal health.
Retinal and Ophthalmic Disease
Curateq Biologics Private Limited is also involved in research for wet age-related macular degeneration, a vision-threatening retinal disorder associated with abnormal angiogenesis and macular fluid accumulation.
- Wet age-related macular degeneration
- Retinal neovascular disease
- Anti-VEGF therapy
The sponsor’s ophthalmic interest centers on biologic treatment comparisons in diseases that affect central vision.
Biosimilar Therapeutics
Across its clinical portfolio, the sponsor shows a strong focus on biosimilar development and therapeutic equivalence assessment in immunology, endocrinology, and ophthalmology.
- Comparative biologic efficacy
- Pharmacodynamic endpoints
- Immunogenicity evaluation
Its funded studies span multiple therapeutic domains where biologic medicines are central to treatment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Comparison of Efficacy and Safety of BP11 and EU-Approved Omalizumab in Chronic Spontaneous Urticaria Resistant to H1 Antihistamines |  Bulgaria Hungary Latvia Lithuania Poland Slovakia | Not Recruiting |
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Compared to Denosumab in Post-Menopausal Osteoporosis Patients | Bulgaria Estonia Hungary Latvia Poland Slovakia | Not Yet Recruiting |
| Phase 3 Randomized Study Comparing Efficacy and Safety of BP05 and Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration | Latvia Slovakia | Not Recruiting |
Data & Insights
This sponsor works with 7 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 103 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases1 trial138 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
- 3.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
103 centres- Address
- Rigas Iela 46a, 2125 Baldone
- Address
- Aleksandra Caka Street 70-3, 1011 Riga
- Address
- Seliu G. 64, Vilniaus M. Sav., 08109 Vilnius
- Address
- Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
- Address
- Marsala Koneva 985/1, 040 22 Košice
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Curateq Biologics Private Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.